

Highlights of This Issue 315

SMALL MOLECULE THERAPEUTICS

- 317** **Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants**
Lindsey N. Micel, John J. Tentler, Aik-Choon Tan, Heather M. Selby, Kelsey L. Brunkow, Kelli M. Robertson, S. Lindsey Davis, Peter J. Klauk, Todd M. Pitts, Esha Gangolli, Robyn Fabrey, Shawn M. O'Connell, Patrick W. Vincent, and S. Gail Eckhardt
- 326** **Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors**
Alexander G. Goglia, Robert Delsite, Antonio N. Luz, David Shahbazian, Ahmed F. Salem, Ranjini K. Sundaram, Jeanne Chiaravalli, Petrus J. Hendrikx, Jennifer A. Wilshire, Maria Jasin, Harriet M. Kluger, J. Fraser Glickman, Simon N. Powell, and Ranjit S. Bindra
- 343** **A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor**
Kazuteru Fukasawa, Shigehide Kagaya, Sakiko Maruyama, Shunsuke Kuroiwa, Kuniko Masuda, Yoshio Kameyama, Yoshitaka Satoh, Yuichi Akatsu, Arihiro Tomura, Kiyohiro Nishikawa, Shigeo Horie, and Yuh-ichiro Ichikawa
- 355** **Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling Pathway**
Qiao Liu, Xiuhua Xu, Minnan Zhao, Zhao Wei, Xi Li, Xiyu Zhang, Zhaojian Liu, Yaoqin Gong, and Changshun Shao
- 364** **Evaluation of the *In Vitro* and *In Vivo* Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia**
Santi Suryani, Lauryn S. Bracken, Richard C. Harvey, Keith C.S. Sia, Hernan Carol, I-Ming Chen, Kathryn Evans, Philipp A. Dietrich, Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter Houghton, Malcolm A. Smith, and Richard B. Lock
- 375** **AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia**
Cong Li, Liqin Liu, Lingming Liang, Zhen Xia, Zhihong Li, Xianghong Wang, Lawrence R. McGee, Katie Newhall, Angus Sinclair, Alexander Kamb, Dineli Wickramasinghe, and Kang Dai
- 384** **The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in *MET*-Amplified Cancer**
Coumaran Egile, Mireille Kenigsberg, Christine Delaisi, Françoise Bégassat, Véronique Do-Vale, Jessica Mestadier, Fabrice Bonche, Tsiala Bénard, Jean-Paul Nicolas, Sandrine Valence, Céline Lefranc, Elisa Francesconi, Christelle Castell, Anne-Marie Lefebvre, Conception Nemecek, Loreley Calvet, and Hélène Goulaouic
- 395** **MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent *In Vitro* and *In Vivo* Antitumor Activity as Potential Therapy for Bone and Soft-Tissue Sarcoma**
Emily K. Slotkin, Parag P. Patwardhan, Shyamprasad D. Vasudeva, Elisa de Stanchina, William D. Tap, and Gary K. Schwartz
- 407** **A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer**
Youli Pan, Mingwu Zheng, Lei Zhong, Jiao Yang, Shu Zhou, Ya Qin, Rong Xiang, Yuzong Chen, and Sheng-Yong Yang
- 419** **Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma**
Nan Li, Dustin J. Maly, Yvan H. Chanthery, Daniel W. Sirkis, Jean L. Nakamura, Mitchel S. Berger, C. David James, Kevan M. Shokat, William A. Weiss, and Anders I. Persson
- 429** **Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma**
Tongxin Liu, Quanquan Sun, Qi Li, Hua Yang, Yuqin Zhang, Rong Wang, Xiaoshan Lin, Dong Xiao, Yawei Yuan, Longhua Chen, and Wei Wang

Table of Contents

- 440** The Use of Dipeptide Derivatives of 5-Aminolaevulinic Acid Promotes Their Entry to Tumor Cells and Improves Tumor Selectivity of Photodynamic Therapy
Gabriela Di Venosa, Pablo Vallecorsa, Francesca Giuntini, Leandro Mamone, Alcira Batlle, Silvia Vanzuli, Angeles Juarranz, Alexander J. MacRobert, Ian M. Eggleston, and Adriana Casas

- 452** A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages
Noriyuki Hayashi, Hiromi Kataoka, Shigenobu Yano, Mamoru Tanaka, Kazuhiro Moriwaki, Haruo Akashi, Shugo Suzuki, Yoshinori Mori, Eiji Kubota, Satoshi Tanida, Satoru Takahashi, and Takashi Joh

- 461** A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Kari L. Kendra, Ruth Plummer, Ravi Salgia, Mary E. R. O'Brien, Elaine M. Paul, A. Benjamin Suttle, Natalie Compton, Chun-Fang Xu, Lone H. Ottesen, and Miguel A. Villalona-Calero

LARGE MOLECULE THERAPEUTICS

- 470** Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression
Jung-Eun Lee, Chan Kim, Hannah Yang, Intae Park, Nuri Oh, Serenus Hua, Haneul Jeong, Hyun Joo An, Sun Chang Kim, Gyun Min Lee, Gou Young Koh, and Ho Min Kim

- 480** Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
Sheng-Bin Peng, Xiaoyi Zhang, Donald Paul, Lisa M. Kays, Wendy Gough, Julie Stewart, Mark T. Uhlik, Qi Chen, Yu-Hua Hui, Maciej J. Zamek-Gliszczynski, John A. Wijsman, Kelly M. Credille, and Liang Zeng Yan

- 491** SapC-DOPS Nanovesicles as Targeted Therapy for Lung Cancer
Shuli Zhao, Zhengtao Chu, Victor M. Blanco, Yunzhong Nie, Yayi Hou, and Xiaoyang Qi

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 499** Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction
Renata Jaskula-Sztul, Jacob Eide, Sara Tesfazghi, Ajitha Dammalapati, April D. Harrison, Xiao-Min Yu, Casi Scheinebeck, Gabrielle Winston-McPherson, Kevin R. Kupcho, Matthew B. Robers, Amrit K. Hundal, Weiping Tang, and Herbert Chen

- 513** Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Remi Adelaiye, Eric Ciamporcerro, Kiersten Marie Miles, Paula Sotomayor, Jonathan Bard, Maria Tsompana, Dylan Conroy, Li Shen, Swathi Ramakrishnan, Sheng-Yu Ku, Ashley Orillion, Joshua Prey, Gerald Fetterly, Michael Buck, Sreenivasulu Chintala, Georg A. Bjarnason, and Roberto Pili

- 523** Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Netai C. Singha, Tara Nekoroski, Chunmei Zhao, Rebecca Symons, Ping Jiang, Gregory I. Frost, Zhongdong Huang, and H. Michael Shepard

- 533** Combining Onartuzumab with Erlotinib Inhibits Growth of Non-Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Yuji Sano, Eri Hashimoto, Noriaki Nakatani, Masaichi Abe, Yasuko Satoh, Kiyooki Sakata, Toshihiko Fujii, Kaori Fujimoto-Ouchi, Masamichi Sugimoto, Shigehisa Nagahashi, Masahiro Aoki, Hiroshi Motegi, Eiichi Sasaki, and Yasushi Yatabe

- 542** Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
Catherine B. Meador, Hailing Jin, Elisa de Stanchina, Caroline A. Nebhan, Valentina Pirazzoli, Lu Wang, Pengcheng Lu, Huy Vuong, Katherine E. Hutchinson, Peilin Jia, Xi Chen, Rosana Eisenberg, Marc Ladanyi, Katerina Politi, Zhongming Zhao, Christine M. Lovly, Darren A.E. Cross, and William Pao

- 553** HAb18G/CD147 Promotes Radioresistance in Hepatocellular Carcinoma Cells: A Potential Role for Integrin β 1 Signaling
Jiao Wu, Yong Li, Ya-Zheng Dang, Hong-Xiang Gao, Jian-Li Jiang, and Zhi-Nan Chen

Table of Contents

564 Glycogen Synthase Kinase 3 β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway

Yuri Chikano, Takahiro Domoto, Takuya Furuta, Hemragul Sabit, Ayako Kitano-Tamura, Ilya V. Pyko, Takahisa Takino, Yoshimichi Sai, Yutaka Hayashi, Hiroshi Sato, Ken-ichi Miyamoto, Mitsutoshi Nakada, and Toshinari Minamoto

575 Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to Irinotecan

Cornelia Meisenberg, Duncan C. Gilbert, Anthony Chalmers, Vikki Haley, Simon Gollins, Simon E. Ward, and Sherif F. El-Khamisy

586 Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells

Béatrice Dirat, Isabelle Ader, Muriel Golzio, Fabienne Massa, Amel Mettouchi, Kathiane Laurent, Frédéric Larbret, Bernard Malavaud, Mireille Cormont, Emmanuel Lemichez, Olivier Cuvillier, Jean François Tanti, and Frédéric Bost

597 Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity *In Vitro* and *In Vivo*

Su-Jung Kwon, Seul-Ki Lee, Juri Na, Shin-Ai Lee, Han-Sae Lee, Ji-Hye Park, June-Key Chung, Hyewon Youn, and Jongbum Kwon

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

608 Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk *TP53* Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence



Abdullah A. Osman, Marcus M. Monroe, Marcus V. Ortega Alves, Ameeta A. Patel, Panagiotis Katsonis, Alison L. Fitzgerald, David M. Neskey, Mitchell J. Frederick, Sang Hyeok Woo, Carlos Caulin, Teng-Kuei Hsu, Thomas O. McDonald, Marek Kimmel, Raymond E. Meyn, Olivier Lichtarge, and Jeffrey N. Myers

620 *IRS2* Copy Number Gain, *KRAS* and *BRAF* Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Fei Huang, Han Chang, Ann Greer, Stephen Hillerman, Karen A. Reeves, Warren Hurlburt, John Cogswell, Dharmesh Patel, Zhenhao Qi, Craig Fairchild, Rolf-Peter Ryseck, Tai W. Wong, Friedrich G. Finckenstein, Jeffrey Jackson, and Joan M. Carboni




AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

A complex network of hyaluronan (HA) and proteoglycans in the tumor microenvironment with high levels of HA (HA^{high}) forms a physical barrier capable of inhibiting therapeutic monoclonal antibody (mAb) and immune cell access to tumor cells, resulting in a more aggressive tumor phenotype in several solid tumor types. Microscopic cell imaging shows that a physical barrier surrounding HA^{high} tumor cell restricts human NK cells from accessing the tumor cell. These results demonstrate that HA depletion by PEGPH20 removes this barrier and allows increased mAb and immune cell access to the tumor cell, resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC)-dependent tumor cell killing. For details, see the article by Singha and colleagues on page 523.



Molecular Cancer Therapeutics

14 (2)

Mol Cancer Ther 2015;14:315-630.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/14/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/14/2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.